Covered recipient · General Payments record
SERVILLANO DELA CRUZ
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2018–2024
$81,008.27
- Reported across 1,200 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $24,802.00 | 3 |
| Food and Beverage | $2,328.20 | 70 |
| Travel and Lodging | $1,933.56 | 8 |
| Education | $61.99 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| EMD Serono, Inc. | $20,229.41 | 6 |
| Astellas Pharma US Inc | $7,134.05 | 13 |
| Janssen Biotech, Inc. | $211.01 | 4 |
| Incyte Corporation | $204.21 | 5 |
| Merck Sharp & Dohme Corporation | $148.41 | 6 |
| SOBI, INC | $126.46 | 1 |
| PFIZER INC. | $105.21 | 4 |
| Acerta Pharma LLC | $98.62 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $98.14 | 4 |
| GlaxoSmithKline, LLC. | $89.30 | 4 |
| E.R. Squibb & Sons, L.L.C. | $82.75 | 4 |
| TAIHO ONCOLOGY, INC. | $77.62 | 4 |
| EISAI INC. | $71.19 | 3 |
| Alexion Pharmaceuticals, Inc. | $56.18 | 2 |
| Lilly USA, LLC | $44.52 | 2 |
| BeiGene USA, Inc. | $42.13 | 2 |
| Mirati Therapeutics, Inc. | $39.00 | 2 |
| ABBVIE INC. | $30.94 | 1 |
| Daiichi Sankyo Inc. | $27.59 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $27.32 | 1 |
| Gilead Sciences, Inc. | $25.37 | 1 |
| Regeneron Healthcare Solutions, Inc. | $24.48 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $24.15 | 1 |
| GENZYME CORPORATION | $22.32 | 1 |
| Exelixis Inc. | $19.71 | 1 |
| PharmaEssentia USA Corporation | $18.36 | 1 |
| Pharmacosmos Therapeutics Inc. | $17.68 | 1 |
| Tempus AI, Inc | $15.93 | 1 |
| SERVIER PHARMACEUTICALS LLC | $13.69 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (82)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.